文献速递乳腺MR

基于DCE-MRI的影像组学早期预测乳腺癌新辅助治疗病理完全缓解

Radiomics Based on Dynamic Contrast-Enhanced MRI to Early Predict Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Therapy.
PubMed 文献 · Acad Radiol · 2022-12-21

临床-组学模型在训练集和测试集的AUC分别为0.920和0.884,决策曲线分析显示其临床效用优于临床模型。

要点

  • DCE-MRI影像组学可在新辅助治疗早期(两周期后)预测病理完全缓解。
  • 结合临床病理变量与组学评分可提升预测效能(训练集AUC 0.920)。
  • 测试集提升未达统计学显著(DeLong检验 p=0.196),需谨慎解读。

核心结论

  • 基于DCE-MRI的影像组学特征在新辅助治疗早期对病理完全缓解具有预测潜力,联合临床病理特征可获得更高诊断效能。

研究设计与样本

  • 所有患者在新辅助治疗前及两周期后行DCE-MRI,提取T1增强最明显期相的851个影像组学特征及delta、delta%特征。
  • 采用LASSO筛选特征,逻辑回归计算pre-NAT、early-NAT、delta和delta% radscores,并构建融合组学模型及临床-组学模型。

诊断标准与关键数值

  • 融合组学模型基于pre-NAT、Delta和Delta% radscores,训练集AUC为0.868,测试集为0.825。
  • 临床-组学模型整合融合组学评分与临床病理变量,训练集AUC为0.920,测试集为0.884。
  • 临床模型训练集AUC为0.858,测试集为0.831;测试集中临床-组学模型与临床模型AUC差异DeLong检验 p=0.196。
  • 决策曲线分析显示临床-组学模型较临床模型具有更高临床效用。

临床应用与阅片要点

  • 阅片时可关注新辅助治疗前及两周期后DCE-MRI增强最明显期相的肿瘤影像组学特征变化。
  • 联合临床病理变量(如相对肿瘤最大直径回归值diameter%)可辅助提升pCR预测效能。
  • 测试集AUC提升未达统计学显著,模型泛化能力需进一步验证,不宜单独用于临床决策。

局限性

  • 测试集样本量较小(36例),临床-组学模型较临床模型的提升未达统计学显著(p=0.196)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To investigate the value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-based radiomics at baseline and after two cycles of neoadjuvant therapy (NAT) and associated longitudinal changes for early prediction of the NAT response in patients with breast cancer.

MATERIALS AND METHODS: One hundred seventeen patients with breast cancer who underwent DCE-MRI before NAT and after two cycles of NAT from April 2019 to November 2021 were enrolled retrospectively. Patients were randomly divided into a training set (n = 81) and a test set (n = 36) at a ratio of 7:3. Clinical-pathological data and the relative tumor maximum diameter regression value (diameter%) were also collected. A total of 851 radiomic features were extracted from the phase with the most pronounced tumor enhancement on DCE-MRI T1 imaging acquired both pre- and post-treatment. Delta and delta% radiomics features were also calculated. The Least Absolute Shrinkage and Selection Operator (LASSO) method was applied to select features, and a logistic regression model was used to calculate pre-NAT, early-NAT, delta, and delta% radscores and then select among four radscores to build a Fusion radiomics model. The final clinical-radiomics model was constructed by combining fusion radscores and clinical-pathological variables. The discrimination and clinical utility of the models were further evaluated and compared.

RESULTS: The area under the curve (AUC) values of the fusion radiomics model based on pre-NAT, Delta, and Delta% radscores were 0.868 of 0.825. The clinical-radiomics model integrating Fusion radscores and clinical-pathological variables achieved AUC values of 0.920 of 0.884, which were higher than those of the clinical model constructed by AUC values (0.858/0.831), although no significant improvement was observed in the test set (Delong test, p = 0.196). Decision curve analysis (DCA) showed that the clinical-radiomics model demonstrated more clinical utility than the clinical model.

CONCLUSION: DCE-MRI-based radiomics features may have potential for pathological complete response (pCR) prediction in the early phase of NAT. By combining radiomics features and clinical-pathological characteristics, higher diagnostic performance can be achieved.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Zeng, Ke, Zhong, et al. Radiomics Based on Dynamic Contrast-Enhanced MRI to Early Predict Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Therapy. Acad Radiol. 2022. PMID: 36564256. doi:10.1016/j.acra.2022.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。